Telsey Advisory Group analyst Joseph Feldman maintains Nike (NYSE:NKE) with a Outperform and raises the price target from $130 to $133.
Expert Ratings for Cytokinetics
Over the past 3 months, 9 analysts have published their opinion on Cytokinetics (NASDAQ:CYTK) stock. These analysts are…